Short- and Long-Term Effects of LRRK2 on Axon and Dendrite Growth

Bryan Sepulveda1,3*, Roxana Mesias1,3, Xianting Li2, Zhenyu Yue2, Deanna L. Benson1*

1 Department of Neuroscience, Mount Sinai School of Medicine, New York, New York, United States of America, 2 Department of Neurology, Friedman Brain Institute, Mount Sinai School of Medicine, New York, New York, United States of America, 3 Graduate School of Biological Sciences, Mount Sinai School of Medicine, New York, New York, United States of America

Abstract

Mutations in leucine-rich repeat kinase 2 (LRRK2) underlie an autosomal-dominant form of Parkinson’s disease (PD) that is clinically indistinguishable from idiopathic PD. The function of LRRK2 is not well understood, but it has become widely accepted that LRRK2 levels or its kinase activity, which is increased by the most commonly observed mutation (G2019S), regulate neurite growth. However, growth has not been measured; it is not known whether mean differences in length correspond to altered rates of growth or retraction, whether axons or dendrites are impacted differentially or whether effects observed are transient or sustained. To address these questions, we compared several developmental milestones in neurons cultured from mice expressing bacterial artificial chromosome transgenes encoding mouse wildtype-LRRK2 or mutant LRRK2-G2019S, Lrk2 knockout mice and non-transgenic mice. Over the course of three weeks of development on laminin, the data show a sustained, negative effect of LRRK2-G2019S on dendritic growth and arborization, but counter to expectation, dendrites from Lrk2 knockout mice do not elaborate more rapidly. In contrast, young neurons cultured on a slower growth substrate, poly-L-lysine, show significantly reduced axonal and dendritic motility in Lrrk2 transgenic neurons and significantly increased motility in Lrk2 knockout neurons with no significant changes in length. Our findings support that LRRK2 can regulate patterns of axonal and dendritic growth, but they also show that effects vary depending on growth substrate and stage of development. Such predictable changes in motility can be exploited in LRRK2 bioassays and guide exploration of LRRK2 function in vivo.

Introduction

Mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) account for up to 13% of familial Parkinson’s disease (PD) cases. The most common clinical mutation, G2019S, has been reported in almost 7% of familial PD patients with penetrance that is age-dependent—from 21% at age 50 to 81% at age 70 [1,2,3]. The structure of LRRK2 suggests that it is multifunctional; it is a 286 kDa protein that contains several protein-protein interaction domains, a kinase domain, and a GTPase [3]. The G2019S mutation increases LRRK2 kinase activity [4,5,6,7], suggesting that therapies designed to reduce kinase activity may be relevant for treating PD [8]; however, the biological functions of LRRK2 are poorly understood.

Several efforts have been made to identify predictable effects of altered LRRK2 levels or kinase activity in neurons grown in culture that could be used as bioassays as well as to pursue disease-related phenotypes in vivo. Previous work has shown that neurons grown in culture that overexpress LRRK2-G2019S have shorter neurites than non-transgenic neurons, while those cultured from mice with Lrk2 deleted (KO) have longer neurites [9,10,11,12]. These data have led many in the field to believe that LRRK2, and the G2019S mutation in particular, inhibits growth. However, there remain several outstanding questions that suggest that this widely accepted interpretation requires closer examination and clarification. Previous studies have measured neurite length in glutamatergic neurons on a single day [9,10,11], with differences interpreted as either changes in growth or retraction, measures that require longitudinal observations. Neurites have not been parsed into axons and dendrites [8,9,11,12] so it is not known whether shorter lengths could be unique to axons, dendrites or both. It is also not clear whether changes in neurite length reflect altered levels of LRRK2, LRRK2 mutation or even the means by which LRRK2 is introduced in neurons since in vivo observations in bacterial artificial chromosome (BAC) transgenic mouse lines and in LRRK2-KO mice do not exhibit phenotypes consistent with shorter neurites reported in vitro [11,12,13].

Here we used genetic LRRK2 mouse models to determine whether LRRK2 levels or the G2019S mutation altered the establishment of neural polarity, the elaboration of axons and dendrites, and/or the pattern of axon and dendrite growth over the course of development. Our data support a model in which LRRK2 has a consistent effect on dendrite and axon growth that is best revealed on a slow growth substrate using time-lapse imaging.
These data support the use of neurite growth assays as a reflection of LRRK2 actions, but also indicate that such assays need to be utilized with caution.

Results

Mouse Models
To test whether LRRK2 levels and mutation affect neuronal development, we cultured neurons from mouse lines that have been described previously. We used BAC transgenic mouse lines that overexpress either mouse wildtype LRRK2 (LRRK2-WT<sup>OE</sup>) or LRRK2 carrying the G2019S mutation (LRRK2-G2019S<sup>OE</sup>) (13). Because the BAC LRRK2 expression is controlled by the endogenous promoter, the spatio-temporal expression of additional LRRK2 expression resembles the endogenous [13,14,15,16]. Additionally, we investigated the effect of a targeted Lnk2 deletion in neuronal development with Lnk2 knockout (KO; [10]) mice.

Acquisition of Neuronal Polarity Unchanged by LRRK2-WT<sup>OE</sup>, LRRK2-G2019S<sup>OE</sup> or KO
Since LRRK2 is suspected to regulate neurite growth, we asked whether the development of neuronal polarity, an event that is defined by the focused growth of a single process that becomes an axon, is altered by LRRK2 levels or mutation. In hippocampus, LRRK2 is expressed in most neurons beginning in late embryonic stages [14,15,16,17], so we used hippocampal neurons grown in culture as a model. We tested for the acquisition of neuronal polarity in three different ways.

Measurement of all neurites at 24 h reveals that 100% of neurons of all four genotypes had grown one neurite that was at least 10 μm longer than all of the others, which previous work has demonstrated is the axon [18].

Polarity can also be defined by the sorting of axonal and dendritic proteins to their respective subcellular domains. To measure this, neurons were grown for 3 days in vitro (DIV) and labeled for SMI-31, which concentrates in axons as soon as they are generated and MAP2, which becomes enriched in dendrites and excluded from axons over a slower time course [19,20]. To compare polarized distribution among genotypes quantitatively, we generated a polarity index (PI) for MAP2 by dividing the immunofluorescence intensity of SMI-31 by dividing the immunofluorescence intensity of MAP2 in axons (i.e. MAP2<sub>dendrite/axon</sub>)[21] (Fig. 1A–C). An advantage of this assessment is that it is independent of fluorescence intensity levels, which can vary between neurons. Properly polarized neurons have a PI for SMI-31 less than one and for MAP2, greater than one. The data show that axons and dendrites in neurons of all genotypes have appropriately polarized SMI-31 and MAP2 immunolabeling, defined by a ratio of MAP2<sub>dendrite/axon</sub> greater than 1 (Chi-square, p = 0.128) and SMI-31<sub>dendrite/axon</sub> less than 1 (Chi-square, p = 0.090).

Since primary hippocampus neurons can abnormally form multiple axons, we asked whether LRRK2 activity had an effect on multiple axon formation [22,23]. For each genotype, at least 50 neurons in at least two different culture preparations were scored for the presence of multiple axons defined by SMI-31 labeling. Few neurons of any genotype had multiple axons, and there were no significant differences between groups (Chi-square, p = 0.480; NT: 4.49%; KO: 3.45%; LRRK2-WT<sup>OE</sup>: 2.00%; LRRK2-G2019S<sup>OE</sup>: 8.89%).

Axon Growth and Branching are not altered by LRRK2-WT<sup>OE</sup>, LRRK2-G2019S<sup>OE</sup> or KO
To determine whether changes in LRRK2 levels or LRRK2 mutation alter total axon length or branching patterns, SMI-31-labeled axons in neurons cultured on laminin from mice of all four genotypes were traced in their entirety at 3 DIV. Neither total axon length, nor numbers of branches, determined by the number of dendritic branch tips, differed significantly between groups (one-way ANOVA; length, p = 0.61; branches, p = 0.83; Fig. 1D, E).

LRRK2 has Modest Effects on Dendritic Growth and Arborization
Previous work suggests that dendrite length can be affected by LRRK2 levels or mutation [24]. To determine whether such changes reflect altered extension or retraction, whether they are transient or sustained, and/or whether differences observed reflect changes in numbers of primary dendrites or dendritic branches, the dendritic arbors in neurons grown on laminin from all four genotypes were traced in their entirety at 3, 5, 7, 10, 14 and 21 DIV (Fig. 2). A power analysis (see Methods) indicated that measurements from 20 neurons per time point is sufficient to detect even a small effect size, and we set this as a minimum.

When total dendritic lengths per neuron are compared, it can be seen that the growth curve of LRRK2-G2019S<sup>OE</sup> neurons sits below that of all other genotypes (Fig. 3A). Neurons from all genotypes elaborate dendritic arbors over a three week period, but the growth rate for LRRK2-G2019S<sup>OE</sup> neurons is significantly reduced (two-way ANOVA, age, p < 0.0001; genotype, p = 0.0008; Fig. 3A). A post hoc test shows that the differences are greatest at 14 DIV (Fig. 3B).

Several lines of data had led us to predict that KO neurons would display increased dendritic growth relative to all other genotypes (see Introduction). With this in mind, we asked whether growth curves over the first week in culture—a time period that covers most previous studies—differ from later ages. LRRK2-G2019S<sup>OE</sup> dendrites show significantly reduced growth (two-way ANOVA, p < 0.0001 for both genotype and age; Fig. 3C, D). Interestingly, there was a significant increase in KO dendrite growth compared to NT at 5 DIV, but measurements at 3 and 7 DIV showed the reverse with NT dendrites significantly longer than KO.

To determine whether LRRK2 regulates dendritic branching, we compared numbers of primary dendrites and numbers of total branch endings per neuron. There were no significant differences between any of the four genotypes in the number of primary dendrites per neuron (1-way ANOVA, p = 0.64; mean ± SEM of all ages: NT: 4.3 ± 0.4; LRRK2-WT<sup>OE</sup>: 4.5 ± 0.5; KO: 3.9 ± 0.4; LRRK2-G2019S<sup>OE</sup>: 4.0 ± 0.2). Dendrite branch endpoint numbers increase over time and similarly for all genotypes (two-way ANOVA, age, p = 0.001; genotype, p = 0.12; Fig. 3E, F). However, a separate examination of the first week in culture reveals an early effect of genotype on dendrite branching, with LRRK2-G2019S<sup>OE</sup> neurons having fewer dendritic branches than NT and LRRK2-WT<sup>OE</sup> neurons (two-way ANOVA, genotype, p = 0.002; time, p < 0.0001; Fig. 3G, H). Interestingly, KO and LRRK2-G2019S<sup>OE</sup> dendrites also have significantly fewer branches than NT dendrites at 7 DIV. However, these effects are not sustained when data from 10–21 DIV are compared separately (two-way ANOVA, genotype, p = 0.33; time, p < 0.0001).

We asked whether a change in branching patterns could have contributed to the decrease in dendrite growth observed in KO neurons at 21 DIV. The data show that KO neurons have an
exceptionally high number of fifth degree and higher branches at 14 DIV that are lost at 21 DIV (mean ± SEM: 44.9 ± 9.8 branches at 14 DIV; 15.6 ± 3.3 branches at 21 DIV).

Since LRRK2-G2019S OE neurons display more restrained growth rates and slightly diminished branching, and because the LRRK2-G2019SOE mutation has been associated with increased neuron death [6,9,25,26], we asked whether LRRK2-G2019S OE neurons survive as well under our conditions as neurons from other genotypes. At 14 DIV, there were no significant differences in neuron densities between any of the genotypes (one-way ANOVA, p = 0.10).

Time Lapse Imaging and a Slow Substrate Reveal Clear Effect of LRRK2 on Motility

Previous assessments of neurite length at single time points would have predicted that neurites from LRRK2-G2019S OE neurons grow slower than those in NT neurons, while KO neurites grow faster. Consistent with this prediction, our data show decreased rates of dendritic growth in LRRK2-G2019SOE neurons compared to NT and KO, but there is no change in axonal or dendritic growth rates in KO neurons compared to NT. Thus, we asked whether our experimental conditions could be masking an effect on KO neurons. One possibility is that rapid growth on laminin generated a ceiling effect. Laminin is a natural growth substrate that was chosen based on pilot studies because it best supported the survival and maintenance of mouse neurons in culture. However, poly-L-lysine (PLL), an artificial and much slower substrate, has been used in most previous studies to grow cultured neurons [10,11]. Another possibility is that neuron-to-neuron variability masks a modest, but consistent effect.

To address these possibilities, time-lapse imaging was used to track growth on PLL in the same neurites over time. Neurons were imaged every 15 minutes for 7.5 h and two parameters were compared: 1) motility, defined as the absolute value of movement–extension or retraction–in any direction from the starting point; and 2) growth (extension minus retraction).

As expected, axonal growth cones were highly motile, and axons from all genotypes showed periods of extension and retraction throughout the recording period. KO axons displayed significantly increased motility compared to other genotypes. LRRK2-G2019SOE and LRRK2-WT OE axons showed significantly decreased motility relative to NT as well as to KO (Fig. 4A, C). Comparisons of the motility of dendritic growth cones yielded similar results (Fig. 4B, D).

While motility measurements reveal strong differences between genotypes, these differences did not translate ultimately into significant changes in either axon or dendrite growth over the time recorded (Fig. 4E, F; one-way ANOVA; axons, p = 0.054; dendrites, p = 0.172). This is illustrated in Fig. 4G, which shows the initial length of a KO axon (white triangle), steady growth to a
Discussion

Here our data show that LRRK2 regulates axonal and dendritic growth and arborization, but the effects are varied and depend on the substrate on which neurons are grown, neuron age, and whether axons or dendrites are examined. Population studies of fixed neurons grown on laminin carried out over the course of three weeks of development reveal a sustained, negative effect of LRRK2-G2019SOE on dendritic growth and arborization, a finding consistent with previous work [12,24]. Unexpectedly, our findings also reveal a delayed, negative effect of the LRRK2 deletion on dendritic arborization between the second and third weeks in vitro. Imaging neurons grown on PLL over several hours reveals reduced motility in neurons overexpressing either LRRK2-WT^OE or LRRK2-G2019S^OE and heightened motility in neurons lacking LRRK2. Together, our findings support some previous work showing effects of LRRK2 on neurite outgrowth, but they also indicate that neurite growth does not follow a simple correlation with LRRK2 levels and/or mutation, and that outcomes can vary based on the substrate on which neurons are grown and their stage of development.

Several studies have shown that overexpression of LRRK2-G2019S in hippocampal neurons grown in culture [8,9,11], in midbrain neurons in culture [12], or in newly born dentate gyrus granule cells in vivo [24] can result in shorter neurites. Consistent with these findings, our data show decreased dendritic growth in LRRK2-G2019S^OE neurons cultured on laminin. This effect appears to be due to the mutation, and perhaps the increased kinase activity associated with it [4,6,26], rather than overexpression, since dendrites in LRRK2-WT^OE neurons extend and arborize to a similar extent as dendrites in NT neurons. In LRRK2-G2019S^OE neurons, decreased dendritic growth was observed over the entire time course relative to the other genotypes, but the mean differences in growth between genotypes were not dramatic. However, the growth and elaboration of dendritic branches in LRRK2-G2019S^OE neurons show consistent upward slopes, suggesting an eventual recovery. This would be consistent with the absence of overt morphological differences that have been reported in a variety of brain areas in adult LRRK2 mouse models [13,27,28,29], but a developmental delay may be relevant to PD as it could impart vulnerability consistent with the adult onset of PD.

The idea that LRRK2 regulates neurite growth has been based on gain-of-function experiments, in which overexpression of human LRRK2-G2019S produces shorter neurites [9,10,11,12,24] as well as on loss-of-function experiments in which neurons cultured from LRRK2-KO mice produce longer neurites [9,10]. In the current study, the absence of a consistent effect of LRRK2 deletion on either axon or dendrite extension in neurons grown on laminin is likely due to a ceiling effect generated by maximal growth rates achieved by KO and NT neurons. Our experiments carried out on PLL (a slow-growth substrate) lend credence to this interpretation as they show that axons and dendrites extending from KO neurons exhibit significantly greater motility than those from other genotypes. While motility (a measure that encompasses both extension and retraction) did not translate into increased length over 8 h of imaging, axons showed a trend in this direction. By contrast, LRRK2-G2019S^OE neurons showed reduced motility on PLL. However, unlike the long-term studies, where LRRK2-G2019S^OE neurons stand apart, LRRK2-WT^OE neurons also showed reduced motility suggesting that increased levels of LRRK2, rather than the LRRK2-G2019S mutation, are responsible.

To confirm the substrate dependence of our findings we carried out time lapse imaging of neurons cultured on laminin, but extensive cell body migration, consistent with in vivo studies [30],
Figure 3. LRRK2-G2019SOE negatively regulates dendritic growth and branching. Line graph (A) plots total dendritic length per neuron over time for neurons of all four genotypes. Data are shown as mean ± SEM. Table (B) shows results of Bonferroni’s post-tests, indicating the sources of significant differences identified in a two-way ANOVA (see text). *p < 0.05; **p < 0.01; ***p < 0.001, n.s. = not significant. Numbers in parentheses refer to DIV. Line graph (C) is an expanded view of results from the first week of development shown in (A), and the table (D) shows the post hoc analyses from this subset. Line graph (E) plots the total number of dendritic branch points for all genotypes and the table (F) shows the results of Bonferroni’s post-tests. The line graph (G) is an expanded view of the data shown in (E) and the table (H) shows the post hoc analyses from the first week of development. At least 10 neurons from at least two culture preparations each (at least 20 neurons total) were traced and measured per genotype per time point assessed.

doi:10.1371/journal.pone.0061986.g003
**Effects of LRRK2 on Axon and Dendrite Growth**

**A** Cumulative Motility: Axons

**B** Cumulative Motility: Dendrites

**C**

|          | NT | KO | WT\textsuperscript{OE} | GS\textsuperscript{OE} |
|----------|----|----|-------------------------|------------------------|
| NT       |    |    | **                      | **                     |
| KO       |    |    | ***                     | ***                    |
| WT\textsuperscript{OE} |    | n.s. |                       |                        |
| GS\textsuperscript{OE} |    |    |                         |                        |

**D**

|          | NT | KO | WT\textsuperscript{OE} | GS\textsuperscript{OE} |
|----------|----|----|-------------------------|------------------------|
| NT       |    |    | ***                     | ***                    |
| KO       |    |    | ***                     | ***                    |
| WT\textsuperscript{OE} |    |    | n.s.                   |                        |
| GS\textsuperscript{OE} |    |    |                         |                        |

**E** Axon Growth

**F** Dendrite Growth

**G**

- **t = 0**
- **t = 2 h**
- **t = 4 h**
- **t = 6 h**
- **t = 7.5 h**
on PLL.

Line graphs plot cumulative motility of axons (A) and dendrites (B) over 7.5 hours. Data shown are mean cell metabolism [6,9,25,26]. In either case, systematic investigation suggests that either a substrate common to both may be involved, [7,38,39]. The effects of LRRK2 on both axons and dendrites decorate microtubules and presumably alter their dynamics to phosphorylate additional targets that might be expected to alter patterns of neurite extension. However, LRRK2 has been posited [33,34], regulate surface expression of cell adhesion proteins and activity correlates with increased ERM phosphorylation and overexpression, but it is not clear whether human LRRK2 protein. Human BAC clones may partly mitigate effects of the overexpression of an extremely large (286 kDa) exogenous human LRRK2 protein or that some observations result from the changes observed are sustained over time is not known. Nevertheless, data from the two independent approaches collectively support that LRRK2 has modest, but consistent effects on the pattern of neurite extension with G2019S OE generally reducing motility and dendrite growth and LRRK2 deletion generally increasing motility. How changes in motility translate into length depends on the environment in which neurons are growing. In vivo, it might be anticipated that axonal extension along tracts or areas enriched with laminin or other growth promoting substrates would be less affected by LRRK2 than the growth of terminal arbors or dendrites within neural parenchyma.

Consistent developmental growth defects seen in culture are likely to have lasting consequences in vivo. While this has not yet been investigated, there are some data that support that dendritic arborization in vivo can be altered by LRRK2. Reconstructions of GFP-labeled neurons show decreased dendrite length and branching in newly generated, adult-born dentate gyrus granule cells overexpressing human LRRK2-G2019S compared to non-transgenic controls [24], and in a related study, doublecortin immunolabeling suggests that dendrites may be more elaborate in LRRK2-KO compared to non-transgenic controls [31]. Whether the changes observed are sustained over time is not known. The effects reported here are less dramatic than might be anticipated based on previous work [9,10,11,12,24]. This is most likely due to differences in growth substrates as described above, but may also be related to differences in genetic models. Previous studies assessing changes in neurite length used overexpression of human rather than mouse LRRK2 [10,11,12,24]. Thus, it remains possible that there is something inherently different about the human LRRK2 protein or that some observations result from the overexpression of an extremely large (286 kDa) exogenous protein. Human BAC clones may partly mitigate effects of overexpression, but it is not clear whether human LRRK2 regulatory elements are recognized and regulated in mouse the same way as mouse LRRK2.

How LRRK2 regulates growth is not known. Moesin, a member of the ERM (Ezrin, Radixin, Moesin) family has been identified as a putative LRRK2 target [32] and increased LRRK2 activity correlates with increased ERM phosphorylation and decreased axon extension [10]. ERMs cap actin filaments [33,34], regulate surface expression of cell adhesion proteins and guidance cues [33,35], and alter axon branching [35,36], making them especially appealing as LRRK2 effectors for changing patterns of neurite extension. However, LRRK2 has been posited to phosphorylate additional targets that might be expected to alter growth, such as Futsch, a MAP1b ortholog [37]. In addition, certain forms of LRRK2 can generate filamentous structures that decorate microtubules and presumably alter their dynamics [7,38,39]. The effects of LRRK2 on both axons and dendrites suggest that either a substrate common to both may be involved, or that some effects may lie downstream of more general effects on cell metabolism [6,9,25,26]. In either case, systematic investigation of LRRK2 substrates will likely prove useful for identifying the relevant signaling pathways.

In summary, our data show that long-term genetic manipulations of LRRK2 expression can produce altered patterns of axonal and dendritic growth, but the effects observed vary with the substrate used. In neurons grown on laminin, LRRK2-G2019S OE slows dendritic growth, but has no effect on the development of polarity or axon growth and arborization. Also on laminin, neurons lacking LRRK2 show normal dendritic growth and arborization through the first two weeks of development after which dendritic arbors show a reduction in terminal branching. On PLL, time lapse imaging shows that KO neurons have more motile axonal and dendritic growth cones compared to NT neurons while LRRK2-G2019S OE and LRRK2-WT OE neurons are less motile than NT neurons. Collectively these data support the idea that LRRK2 can regulate patterns of neurite growth–a finding that may translate into a developmental delay or modest alterations in connectivity. Even a modestly altered course of development could impart vulnerability to environmental influences providing a substrate for a “two-hit” model of PD.

Methods

Mouse Models

Mice overexpressing mouse wildtype LRRK2 (LRRK2-WT OE), or mouse LRRK2-G2019S (LRRK2-G2019S OE), using enogencous promoters were developed as previously described [13], LRRK2 knockout (KO) mice were generated by the Huaibin Cai lab (National Institutes of Health, Bethesda, MD) [10] and obtained from Jackson Laboratories. Non-transgenic (NT) C57/B6 mice were obtained from Charles River Laboratories or from KO littermates. All of the mutant strains used were congenic on an inbred background and backcrossed to their original background.

Mice were housed in the Center for Comparative Medicine at the Mount Sinai School of Medicine. All use of animals was carried out according to protocols that were approved by, and conformed to the guidelines established by, Mount Sinai’s Institutional Animal Care and Use Committee and those of the National Institutes of Health.

Postnatal day 1 (P1) mice were anesthetized by hypothermia and quickly decapitated. Hippocampi were dissected and cells dissociated in 0.1% papain, 2.5 mM HEPES (Invitrogen) and 0.1% trypsin inhibitor solution (pH = 7.7). The hippocampal neurons were plated on cover slips coated with poly-L-lysine (PLL; 1 mg/ml; Sigma) alone for 1 day in vitro (DIV) time lapse imaging or PLL followed by laminin (15 μg/ml; Sigma) for all other assays. Cells were plated at a density of 2.0 × 10^5 cells per plate (4.0 × 10^4 cells per cover slip; 4.0 × 10^4 cells/cm²). Neurons were allowed to adhere for 3 h in Minimum Essential Media (Invitrogen) containing 10% fetal bovine serum (Invitrogen) and 15% sucrose and then transferred to Neurobasal Media (Invitrogen) containing NS21 [40] in a 5% CO₂, 37°C incubator until live imaging or fixation.
Immunocytochemistry

Cultured neurons were fixed in 4% paraformaldehyde/4% sucrose for 15 minutes at room temperature (RT) and permeabilized with 0.25% Triton X-100 (Sigma) for 5 minutes at RT. Nonspecific binding was blocked by incubation in 10% bovine serum albumin (BSA) (Sigma) for 1 h at RT. Primary antibodies were diluted in 1% BSA to the appropriate concentration and incubated for 16 h at 4°C. The primary antibodies used include: anti-rabbit polyclonal MAP2 (1:5000, Abcam, Cambridge, MA) and anti-mouse monoclonal SMI-31 (1:5000, Abcam, Cambridge, MA). After washing, fluorophore-conjugated secondary antibodies were added for 1 h at RT; anti-mouse DyLight 488 (1:1200), anti-rabbit DyLight 488 (1:1200), anti-mouse DyLight 649 (1:1200), anti-mouse Cy3 (1:400) (all from Jackson Immunoresearch). Images were acquired on a Zeiss 510 confocal laser scanning microscope.

Neuronal polarity

Neurons of each phenotype fixed at 3 DIV were labeled for MAP2 and SMI-31 to identify dendrites and axons, respectively. Fluorescence intensities were measured using MetaMorph (Molecular Devices, Sunnyvale, CA). Intensity levels along three 25-pixel-width line segments (1024 × 1024 pixel-images) were assessed and averaged for both MAP2 and SMI-31 immunofluorescence in one dendrite and in the axon of each neuron. Axonal polarity indices were determined by SMI-31 intensity in dendrites divided by SMI-31 fluorescence in axons (SMI-31D/A). Dendritic polarity indices were determined by corresponding quotients of MAP2 intensities (MAP2D/A).

Axon and dendrite outgrowth of fixed neurons

Axons were traced using SMI-31 labeling at 3 DIV neurons using Neurolucida (MBF Bioscience, Williston, VT) to determine length and branching. Dendrites were traced using MAP2 labeling in neurons fixed at 3, 5, 7, 10, 14 and 21 DIV to compare the number of dendrites per neuron as well as the total dendrite length and dendrite branching between neurons of the different genotypes at these ages.

Statistics

Statistical comparisons between groups were made using Prism 5.0 (GraphPad Software, La Jolla, CA). One-way ANOVA was used for comparisons between genotypes at a single time point and two-way ANOVA was used for comparisons between genotypes over time. For ANOVAs yielding significant differences, the source(s) of difference was determined using Bonferroni’s post hoc test. The number of neurons that needed to be traced for the axon and dendrite analyses was estimated by a power analysis (G*Power 3, University of Duesseldorf, Duesseldorf, Germany), which indicated that for a small-sized effect (f = 0.10) between four different groups (genotypes) to be detected at a power of 0.95, at least 20 measurements were needed per genotype. Sample sizes for given experiments are provided in the figure legends.

Time lapse imaging

Neurons were cultured in a 12-well tissue culture plate coated with PLL alone at a density of 4 × 10^4 per well in Neurobasal + NS21 for 24 hours at 37°C and 5% CO2. Neurons were imaged for 7.5 hours at 15-minute intervals in a temperature- and CO2-controlled chamber, using a Zeiss AxioObserver Z1 with a 20 × objective. Axons were defined as the longest process by a difference of at least 10 μm. Axons and dendrites were traced using MetaMorph.

Acknowledgments

The authors wish to thank Lauren Friedman for critical reading of the manuscript.

Author Contributions

Conceived and designed the experiments: BS DLB. Performed the experiments: BS RM. Analyzed the data: BS RM DLB. Contributed reagents/materials/analysis tools: XL ZY DLB. Wrote the paper: BS DLB.

References

1. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, et al. (2004) Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology. Neuron 44: 601–607.
2. Di Fonzo A, Rohe C, Ferreira J, Chien H, Vacca L, et al. (2005) A frequent gene mutation associated with autosomal dominant Parkinson’s disease. The Lancet 365: 412–415.
3. Paisán-Ruiz C, Jain S, Evans EW, Gilks WP, Simón J, et al. (2004) Cloning of the gene containing mutations that cause park2-linked Parkinson’s disease. Neuron 44: 593–600.
4. West A, Moore D, Biskup S, Bugayenko A, Smith W, et al. (2005) Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proceedings of the National Academy of Sciences 102: 16892–16897.
5. Gloeckner C, Kinkel N, Schumacher A, Braun R, O’Neill E, et al. (2005) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Human Molecular Genetics 15: 223–232.
6. Smith W, Pei Z, Jiang H, Dawson V, Dawson T, et al. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nature Neuroscience 9: 1231–1233.
7. Gillaud F. (2009) Leucine-rich repeat kinase 2 phosphorylates brain tubulin beta isoforms and modulates microtubule stability-a point of convergence in Parkinsonian neurodegeneration? Journal of Neurochemistry 110: 1314–1322.
8. Sheng Z, Zhang S, Bustos D, Kleinheinz T, Le Fichon CE, et al. (2012) Ser1292 phosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations. Science Translational Medicine 4: 164ra161.
9. MacLeod D, Dowman J, Hammond R, Lette T, Inoue K, et al. (2006) The Fetal Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology. Neuron 52: 587–593.
10. Paixão-Ruiz C, Jain S, Gilks WP, Simón J, et al. (2004) Cloning of the gene containing mutations that cause park2-linked Parkinson’s disease. Neuron 44: 593–600.
11. Dachsel JC, Behrouz B, Yue M, Beevers JE, Melrose HL, et al. (2010) A comparative study of Lrrk2 function in primary neuronal cultures. Parkinsonism & Related Disorders 16: 650–655.
12. Ramonet D, Daher JP, Lin BM, Stafa K, Kim J, et al. (2011) Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2. PLoS ONE 6: e18568.
13. Li X, Patel JC, Wang J, Advashalom MV, Nicholson C, et al. (2010) Enhanced Striatal Dopamine Transmission and Motor Performance with LRRK2 Overexpression in Mice Is Eliminated by Familial Parkinson’s Disease Mutation G2019S. Journal of Neuroscience 30: 17088–17097.
14. Li X, Tan Y-C, Poulose S, Olanow CW, Huang X-Y, et al. (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutants. Journal of Neurochemistry 105: 238–247.
15. Higashi S, Moore DJ, Colebrooke RE, Biskup S, Dawson VL, et al. (2007) Expression and localization of Parkinson’s disease-associated leucine-rich repeat kinase 2 in the mouse brain. Journal of Neurochemistry 100: 368–381.
16. Tayman JM, Van den Haute C, Backeljau V (2006) Distribution of PINK1 and LRRK2 in rat and mouse brain. Journal of Neurochemistry 98: 951–961.
17. Biskup S, Moore DJ, Celi F, Higashi S, West AB, et al. (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Annals of Neurology 60: 537–569.
18. Godin K, Banker G (1989) Experimental observations on the development of polarity by hippocampal neurons in culture. The Journal of Cell Biology 108: 1507–1516.
19. Casarosa A, Banker GA, Binder L (1986) Immunocytochemical localization of tubulin and microtubule-associated protein 2 during the development of hippocampal neurons in culture. The Journal of Neuroscience 6: 714–722.
20. Benson DL, Mandell JW, Shaw G, Banker G (1996) Compartmentation of alpha-interneuron and neurofilament triplet proteins in cultured hippocampal neurons. J Neurocytol 25: 101–196.
21. Mandell JW, Banker GA (1995) The microtubule cytoskeleton and the development of neuronal polarity. Neurobiology of Aging 16: 229–237.

22. Yoshimura T, Arimura N, Kawano Y, Kawabata S, Wang S, et al. (2006) Ras regulates neuronal polarity via the PI3-kinase/Akt/GSK-3β/CRMP-2 pathway. Biochemical and Biophysical Research Communications 340: 62–68.

23. Hammond JW, Huang C-F, Kaech S, Jacobson C, Banker G, et al. (2010) Posttranslational Modifications of Tubulin and the Polarized Transport of Kinesin-1 in Neuron. Molecular Biology of the Cell 21: 572–583.

24. Winner B, Melrose HL, Zhao C, Hinkle KM, Yue M, et al. (2011) Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiology of Disease 41: 706–716.

25. Greggio E, Jain S, Kingbury A, Bandopadhyay R, Lewis P, et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiology of Disease 23: 329–341.

26. West AB, Moore DJ, Choi C, Andrabi SA, Li X, et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Human Molecular Genetics 16: 223–232.

27. Tong Y, Yamaguchi H, Gainee E, Boyle S, Kopan R, et al. (2010) Loss of leucine-rich-repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice. Proceedings of the National Academy of Sciences 107: 9679–9684.

28. Andres-Mateos E, Mejias R, Sasaki M, Li X, Lin BM, et al. (2009) Unexpected Lack of Hypersensitivity in LRRK2 Knock-Out Mice to MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine). The Journal of Neuroscience 29: 15046–15050.

29. Melrose HL, Kent CB, Taylor JP, Dachsel JC, Hinkle KM, et al. (2007) A comparative analysis of leucine-rich-repeat kinase 2 [Lrk2] expression in mouse brain and Lewy body disease. Neuroscience 147: 1047–1052.

30. Radner S, Banos C, Bachay G, Li YN, Hunter DD, et al. (2012) β2 and γ3 laminins are critical cortical basement membrane components: Ablation of Lamb2 and Lamb3 genes disrupts cortical laminolation and produces dysplasia. Developmental Neurobiology. doi: 10.1002/dneu.22057.

31. Paus M, Kohl Z, Ben Abdallah NM, Galter D, Gillardon F, et al. (2013) Enhanced dendritogenesis and axogenesis in hippocampal neuroblasts of LRRK2 knockout mice. Brain Research http://dx.doi.org/10.1016/j.brainres.2012.10.024.

32. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, et al. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson’s disease mutants affect kinase activity. Biochemical Journal 405: 307–314.

33. Minz CD, Carrea I, McNickle DG, Dickson TC, Ge Y, et al. (2008) ERM proteins regulate growth cone responses to Sema3A. The Journal of Comparative Neurology 510: 351–366.

34. Sato N, Yonezawa S, Ohnata T, Tsuiki T (1993) Radixin, a barbed end-capping actin-modulating protein, is concentrated at the cleavage furrow during cytokinesis. The Journal of Cell Biology 113: 321–330.

35. Dickson TC, Minz CD, Benson DL, Salton SRJ (2002) Functional binding interaction identified between the axonal CAM L1 and members of the ERM family. The Journal of Cell Biology 157: 1105–1112.

36. Cheng I, Koh K, Lemmon V (2005) L1-Mediated Branching Is Regulated by Two Ezrin-Radixin-Moesin (ERM)-Binding Sites, the RSLE Region and a Novel Juxtamembrane ERM-Binding Region. Journal of Neuroscience 25: 393–403.

37. Lee S, Liu HP, Lin WY, Guo H, Lu B (2010) LRRK2 Kinase Regulates Synaptic Morphology through Distinct Substrates at the Presynaptic and Postsynaptic Compartments of the Drosophila Neuromuscular Junction. Journal of Neuroscience 30: 16059–16069.

38. Kritt LR, Boassa D, Ho CC-Y, Rideout HJ, Hu J, et al. (2012) LRRK2 Parkinson disease mutations enhance its microtubule association. Human Molecular Genetics 21: 890–899.

39. Alegre-Abarrategui J, Christian H, Lufino MMP, Mutihac R, Venda LL, et al. (2009) LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Human Molecular Genetics 18: 4022–4034.

40. Chen Y, Stevens B, Chang J, Milbrandt J, Barres BA, et al. (2008) NS21: Re-defined and modified supplement B27 for neuronal cultures. Journal of Neuroscience Methods 171: 239–247.